FDA Approves Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
The U.S. Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech), the first and only PD-(L)1 inhibitor for subcutaneous (SC) injection, for all patients with IV indications for Tecentriq, including those with certain types of skin, lung, liver, and soft tissue cancer. Tecentriq Hybreza can be injected subcutaneously over approximately seven […]